Tomlinson and co-workers have also shown that the expression of FGFR3 is higher in a subset of tamoxifen-resistant ER+ breast cancers with respect to tamoxifen-sensitive ER+ breast tumors [82]. This evidence concerns the gene ESR1 and breast neoplasm.